Lumira invests in First Aid Shot Therapy's $24 mln Series C round

U.S.-based consumer healthcare company First Aid Shot Therapy (FAST) has closed a US$24 million Series C financing. Johnson & Johnson Innovation-JJDC led the round and was joined by new investor Lumira Capital, a Canadian venture capital firm. Sofinnova Ventures, Redmile Group, HealthQuest Capital and other existing investors also participated. FAST, which provides over-the-counter medicine in liquid shot form, said the funding will be used to expand its product portfolio and support growth of its customer base. With the round's close, Lumira Managing General Partner Peter van der Velden has joined the company's board of directors.

CanadaNorth AmericaBriefs